The stock of CERo Therapeutics Holdings Inc (CERO) has seen a 44.26% increase in the past week, with a 5.29% gain in the past month, and a -64.11% decrease in the past quarter. The volatility ratio for the week is 24.28%, and the volatility levels for the past 30 days are at 17.22% for CERO. The simple moving average for the past 20 days is 20.85% for CERO’s stock, with a -89.57% simple moving average for the past 200 days.
Is It Worth Investing in CERo Therapeutics Holdings Inc (NASDAQ: CERO) Right Now?
Company’s 36-month beta value is 0.54.Analysts have differing opinions on the stock, with 1 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for CERO is 3.81M, and currently, short sellers hold a 8.12% ratio of that floaft. The average trading volume of CERO on April 28, 2025 was 1.83M shares.
CERO) stock’s latest price update
CERo Therapeutics Holdings Inc (NASDAQ: CERO) has experienced a decline in its stock price by -19.81 compared to its previous closing price of 1.11. However, the company has seen a gain of 44.26% in its stock price over the last five trading days. globenewswire.com reported 2025-04-25 that SOUTH SAN FRANCISCO, Calif, April 25, 2025 (GLOBE NEWSWIRE) — CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces it will be presenting a poster at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting to be held May 30-June 3, 2025 at McCormick Place, Chicago, Ill.
CERO Trading at -20.00% from the 50-Day Moving Average
After a stumble in the market that brought CERO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -99.48% of loss for the given period.
Volatility was left at 17.22%, however, over the last 30 days, the volatility rate increased by 24.28%, as shares surge +16.35% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -50.55% lower at present.
During the last 5 trading sessions, CERO rose by +44.26%, which changed the moving average for the period of 200-days by -95.41% in comparison to the 20-day moving average, which settled at $0.7365. In addition, CERo Therapeutics Holdings Inc saw -85.16% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CERO starting from YK Bioventures Opportunities G, who sale 2,998,908 shares at the price of $0.06 back on Dec 13 ’24. After this action, YK Bioventures Opportunities G now owns 13,005,169 shares of CERo Therapeutics Holdings Inc, valued at $179,934 using the latest closing price.
YK Bioventures Opportunities G, the 10% Owner of CERo Therapeutics Holdings Inc, sale 1,614,541 shares at $0.07 during a trade that took place back on Dec 12 ’24, which means that YK Bioventures Opportunities G is holding 16,004,077 shares at $113,018 based on the most recent closing price.
Stock Fundamentals for CERO
Current profitability levels for the company are sitting at:
- -13.93 for the present operating margin
The net margin for CERo Therapeutics Holdings Inc stands at -9.54. The total capital return value is set at 13.55. Equity return is now at value -4090.08, with -103.40 for asset returns.
Based on CERo Therapeutics Holdings Inc (CERO), the company’s capital structure generated -4.94 points at debt to capital in total, while cash flow to debt ratio is standing at -3.68.
Currently, EBITDA for the company is -16.2 million with net debt to EBITDA at 0.16. When we switch over and look at the enterprise to sales, we see a ratio of 2.78. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.49.
Conclusion
In a nutshell, CERo Therapeutics Holdings Inc (CERO) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
